Related Experiment Videos
Systemic antimicrobial therapy of nosocomial pneumonia: monotherapy versus combination therapy
1Department of Medicine, Genesee Hospital, Rochester, New York.
Abstract:
The treatment of nosocomial pneumonia is difficult because of the absence of a precise microbial etiology in a sizable fraction of cases and the severity of predisposing conditions in patients who develop these infections. Staphylococcus aureus and aerobic gram-negative rods continue to be the most common isolates in these infections. Therapy of nosocomial pneumonia is often empiric, with initial antimicrobial therapy based upon local experience and sensitivity patterns, immune competence of the patient and disease severity. Combination therapy with an aminoglycoside and a beta-lactam has long been the cornerstone of therapy, and clinical success has been correlated with peak serum bactericidal levels of 1:8 in non-granulocytopenic patients and peak gentamicin and tobramycin levels greater than 8 micrograms/ml. The introduction of new broad-spectrum antibiotics, such as monobactams, third-generation cephalosporins and imipenem, has introduced the possibility of monotherapy for the treatment of nosocomial pneumonia. In general, monotherapy has proven to be a useful alternative to combination therapy, with success rates ranging from 77 to 96%. Development of resistance during therapy, particularly by Pseudomonas, Enterobacter and Serratia spp., remains an unresolved problem.
Insights
Treating nosocomial pneumonia is challenging due to unknown causes and patient conditions. While combination therapy was standard, newer antibiotics allow effective monotherapy for these difficult infections.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Pharmacology
Background:
- Nosocomial pneumonia presents treatment challenges due to uncertain microbial causes and patient comorbidities.
- Staphylococcus aureus and aerobic gram-negative rods are primary pathogens.
- Empiric antimicrobial therapy is common, guided by local resistance patterns and patient factors.
Purpose of the Study:
- To review the challenges and evolving therapeutic strategies for nosocomial pneumonia.
- To evaluate the role of monotherapy versus combination therapy in treating these infections.
Main Methods:
- Review of existing literature on nosocomial pneumonia treatment.
- Analysis of antimicrobial therapy approaches, including combination and monotherapy.
Main Results:
- Combination therapy with aminoglycosides and beta-lactams was historically standard, with success linked to specific serum bactericidal levels.
- Newer broad-spectrum antibiotics (monobactams, third-generation cephalosporins, imipenem) enable monotherapy.
- Monotherapy demonstrates high success rates (77-96%) as an alternative to combination therapy.
Conclusions:
- Monotherapy is a viable and effective alternative for treating nosocomial pneumonia.
- Antimicrobial resistance, especially from Pseudomonas, Enterobacter, and Serratia species, remains a significant challenge requiring ongoing attention.